LIFEVANTAGE CORP Deferred Federal Income Tax Expense (Benefit)
LIFEVANTAGE CORP (LFVN) reported Deferred Federal Income Tax Expense (Benefit) of $519.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-08-27
- LIFEVANTAGE CORP deferred federal income tax expense (benefit) for fiscal 2026 was $519.00K.
- LIFEVANTAGE CORP deferred federal income tax expense (benefit) for fiscal 2025 was -$1.46M.
- LIFEVANTAGE CORP deferred federal income tax expense (benefit) for fiscal 2024 was -$1.28M.
- LIFEVANTAGE CORP deferred federal income tax expense (benefit) for fiscal 2023 was -$1.40M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2026-06-30 | $519.00K 10-K · filed 2026-08-27 |
| 2025-06-30 | -$1.46M 10-K · filed 2026-08-27 |
| 2024-06-30 | -$1.28M 10-K · filed 2025-09-04 |
| 2023-06-30 | -$1.40M 10-K · filed 2024-08-28 |
| 2022-06-30 | -$391.00K 10-K · filed 2023-08-28 |
| 2021-06-30 | $897.00K 10-K · filed 2022-08-23 |
| 2020-06-30 | $316.00K 10-K · filed 2022-08-23 |
| 2019-06-30 | $502.00K 10-K · filed 2021-08-19 |
| 2018-06-30 | $377.00K 10-K · filed 2020-08-18 |
| 2017-06-30 | -$473.00K 10-K · filed 2019-08-14 |
| 2016-06-30 | -$2.33M 10-K · filed 2018-08-15 |
| 2015-06-30 | $97.00K 10-K · filed 2017-09-07 |
| 2014-06-30 | $2.30M 10-K · filed 2016-12-12 |
| 2013-06-30 | -$706.00K 10-K · filed 2015-09-01 |
| 2012-06-30 | -$2.11M 10-K · filed 2014-09-10 |
| 2011-06-30 | $0.00 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |